The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients

European Journal of Cancer

Volumn 44, Issue 3, 2008, Pages 353-365

  Zielinski, Christoph C ^a   Awada, Ahmad ^b   Cameron, David A ^c   Cufer, Tanja ^c   Martin, Miguel ^d   Aapro, Matti ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JULES BORDET INSTITUTE   (Belgium)

^c Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Breast cancer; EORTC; European; Febrile neutropenia; G CSF; Granulocyte colony stimulating factor

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; TRASTUZUMAB;

ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; BREAST RECONSTRUCTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG USE; FEBRILE NEUTROPENIA; HUMAN; MEDICAL RESEARCH; MEDICAL SOCIETY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK ASSESSMENT; THERAPY DELAY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 39149083085     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.11.024     Document Type: Article

References (90)

1. Sausville E.A., and Longo D.L. Principles of cancer treatment: surgery, chemotherapy, and biologic therapy. In: Kasper D.L., Baunwald E., Fauci A.S., et al. (Eds). Harrison's principles of internal medicine. 16th ed. (2005), McGraw-Hill, New York 464-481
2. Crawford J., Dale D.C., and Lyman G.H. Chemotherapy-induced neutropenia. Cancer 100 (2004) 228-237
3. Komroki R.S., and Lyman G.H. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther 4 (2004) 1897-1910
4. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453
5. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., and Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106 (2006) 2258-2266
6. Bonadonna G., Moliterni A., Zambetti M., et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. Br Med J 330 (2005) 217-222
7. Chirivella I., Bermejo B., Insa A., et al. Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol 24 18S (2006) [abstract 668]
8. Schwenkglenks M., Jackisch C., Constenla M., et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 14 (2006) 901-909
9. Mayordomo J.M., Castellanos J., Pernas S., et al. Cost analysis of febrile neutropenia management of breast cancer patients in clinical practice in Spain. J Clin Oncol 24 18S (2006) [abstract 6089]
10. Kuderer N.M., Dale D.C., Crawford J., and Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25 (2007) 3158-3167
11. Smith T.J., Khatcheressian J., Lyman G.H., et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
12. National Comprehensive Cancer Network. Myeloid growth factors. Practice guidelines in oncology v.1.2006. [accessed 16.10.2007].
13. Ozer H., Armitage J.O., Bennett J.L., et al. Update of recommendations for the used of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18 (2000) 3558-3585
14. Hryniuk W.M. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol (1988) 121-141
15. Repetto L., Biganzoli L., Koehne C.H., et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39 (2003) 2264-2272
16. Spielmann M., Roché H., Delozier T., et al. Safety analysis from PACS 04 - A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2 + patients: preliminary results. J Clin Oncol 24 18S (2006) [abstract 632]
17. Martin M., Pienkowski T., Mackay J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (2005) 2302-2313
18. Martin M., Lluch A., Segui{dotless}́ M.A., et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17 (2006) 1205-1212
19. Roché H., Fumoleau P., Spielmann M., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24 (2006) 5664-5671
20. Lopez M., Brandi M., Foggi P., et al. Toxicity of epirubicin and cyclophosphamide (EC) vs. docetaxel (D) followed by EC in the adjuvant (adj) treatment of node positive breast cancer. A multicenter randomized phase III study (GOIM9902). J Clin Oncol 24 18S (2006) [abstract 10526]
21. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19 (2001) 602-611
22. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 (2003) 1431-1439
23. Jones S., Savin M., Holmes F., et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24 (2006) 5381-5387
24. Fumoleau P., Chauvin F., Namer M., et al. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. J Clin Oncol 19 (2001) 612-620
25. Levine M.N., Bramwell V.H., Pritchard K.I., et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16 (1998) 2651-2658
26. Ron I.G., Wigler N., Borovik R., et al. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer. Am J Clin Oncol 24 (2001) 323-327
27. National Comprehensive Cancer Network. Myeloid growth factors. 2005. [accessed 07.09.2005].
28. Coudert B.P., Arnould L., Moreau L., et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17 (2006) 409-414
29. Schmid P., Krocker J., Jehn C., et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol 16 (2005) 1624-1631
30. Ellis G.K., Green S.J., Russell S.A., et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 24 18S (2006) [abstract LBA537]
31. Hurley J., Doliny P., Reis I., et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24 (2006) 1831-1838
32. Nabholtz J.-M., Falkson C., Campos D., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21 (2003) 968-975
33. Alba E., Martin M., Ramos M., et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22 (2004) 2587-2593
34. Perez E.A., Geeraarts L., Suman V.J., et al. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol 13 (2002) 1225-1235
35. Biganzoli L., Cufer T., Bruning P., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20 (2002) 3114-3121
36. Passardi A., Massa I., Zoli W., et al. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. BMC Cancer (2006). [accessed 16.10.2007]
37. Pegram M.D., Pienkowski T., Northfelt D.W., et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96 (2004) 759-769
38. Zielinski C., Beslija S., Mrsic-Krmpotic Z., et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 23 (2005) 1401-1408
39. Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19 (2001) 1707-1715
40. Albain K.S., Nag S., Calderillo-Ruiz G., et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 22 14S (2004) 510. Extra information from oral presentation available from
41. Ghosn M., Kattan J., Farhat F., et al. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 26 (2006) 2451-2456
42. Nabholtz J.-M., Cantin J., Chang J., et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 3 (2002) 268-275
43. Freyer G., Delozier T., Lichinister M., et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21 (2003) 35-40
44. Fuentes H., Calderillo G., Alexander F., et al. Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs 17 (2006) 565-570
45. ten Tije A.J., Smorenburg C.H., Seynaeve C., et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 40 (2004) 352-357
46. Gasparini G., Gion M., Mariani L., et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 101 (2007) 355-365
47. ®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15 (2004) 440-449
48. Tannock I.F., Boyd N.F., DeBoer G., et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6 (1988) 1377-1387
49. Dinota A., Bilancia D., Romano R., and Manzione L. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer. Breast Cancer Res Treat 89 (2005) 1-3
50. Stöger H., Samonigg H., Krainer M., et al. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomized study with two schedules of granulocyte-macrophage colony stimulating factor. Eur J Cancer 34 (1998) 482-488
51. Bonneterre J., Roché H., Monnier A., et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87 (2002) 1210-1215
52. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812-2823
53. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23 (2005) 1178-1184
54. Donadio M., Ardine M., Berruti A., et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 52 (2003) 147-152
55. Gennatas C., Michalaki V., Mouratidou D., et al. Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer. Anticancer Res 26 (2006) 549-552
56. Levy C., and Fumoleau P. Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?. Cancer Treat Rev 31 Suppl. 4 (2005) S17-S22
57. Norris B., Pritchard K.I., James K., et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18 (2000) 2385-2394
58. Jones S., Winer E., Vogel C., et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13 (1995) 2567-2574
59. Nasr F.L., Chahine G.Y., Kattan J.G., et al. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 5 (2004) 117-122
60. Seo J.H., Oh S.C., Choi C., et al. Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol 59 (2007) 269-274
61. Heinemann V., Stemmler H.J., and Wohlrab A. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 57 (2006) 640-646
62. Nole F., Catania C., Munzone E., et al. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer 6 (2006) 518-524
63. Seidman A.D., Fornier M.N., Esteva F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19 (2001) 2587-2595
64. Perez E.A., Vogel C.L., Irwin D.H., et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19 (2001) 4216-4223
65. Montemurro F., Choa G., Faggiuolo R., et al. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 66 (2004) 38-45
66. ®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14 (2003) 1227-1233
67. Fumoleau P., Largillier R., Clippe C., et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40 (2004) 536-542
68. Vici P., Capomolla E., Foggi P., et al. High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients. J Exp Clin Cancer Res 25 (2006) 39-44
69. Nistico C., Bria E., Agostara B., et al. Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study. Anti-Cancer Drugs 17 (2006) 345-351
70. Gafter-Gvili A., Fraser A., Paul M., and Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142 (2005) 979-995
71. Gafter-Gvili A., Fraser A., Paul M., van de Wetering M., Kremer L., and Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 19 (2005) CD004386
72. van de Wetering M.D., de Witte M.A., Kremer L.C.M., et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 41 (2005) 1372-1382
73. Gafter-Gvili A., Paul M., Fraser A., and Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 59 (2007) 5-22
74. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
75. Lyman G.H., Kuderer N.M., Crawford J., et al. Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J Clin Oncol 24 18S (2006) [abstract 8561]
76. Dranitsaris G., Clemons M., Verma S., et al. Development of a risk prediction model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy. Breast 16 Suppl. 1 (2007) S41
77. Jackisch C., Schwenkglenks M., Leonard R., et al. INC-EU Prospective Observational European Neutropenia Study: preliminary breast cancer results. Eur J Cancer Suppl 4 (2006) 95 [abstract 176]
78. von Minckwitz G, Kümmel S, du Bois A, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2007; Sep 9: [Epub ahead of print].
79. Nitz U.A., Mohrmann S., Fischer J., et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366 (2005) 1935-1944
80. Möbus V.J., Untch M., Du Bois A., et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥4 +LN). First results of an AGO-trial. J Clin Oncol (2004) 22 [abstract 513]
81. Hudis C., Citron M., Berry D., et al. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res Treat 94 Suppl. 1 (2005) S20-S21 [abstract 41]
82. Beslija S., Bonneterre J., Burstein H., et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18 (2007) 215-225
83. Colozza M., de Azambuja E., Personeni N., et al. Achievements in systemic therapies in the pregenomic era of metastatic breast cancer. Oncologist 12 (2007) 253-270
84. Jackisch C. HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist 11 Suppl. 1 (2006) 34-41
85. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23 (2005) 4265-4274
86. Doyle A. Prechemotherapy assessment of neutropenic risk. Oncol Nurse Ed 20 (2006) 32-40
87. Hershman D., Neugut A.I., Jacobson J.S., et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99 (2007) 196-205
88. Ozer H., Ding B., and Dreiling L. The impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy in community practice: interim results of the prospective FIRST study. Commun Oncol 3 (2006) 259-264
89. Holmes F.A., O'Shaughnessy J.A., Vukelja S., et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20 (2002) 727-731
90. Green M.D., Koelbl H., Baselga J., et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14 (2003) 29-35